Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T. cruzi multi-epitope recombinant protein
- Development stage
- Preclinical
- Lead developer
- Universidad Autónoma de Yucatán
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
T. cruzi multi-epitope recombinant protein (also referred to as ME protein) is a recombinant protein vaccine candidate designed for the prevention or treatment of Chagas disease, which is caused by the protozoan parasite *Trypanosoma cruzi*. Developed by researchers at the Universidad Autónoma de Yucatán, Hampton University, and Tulane University, the vaccine consists of nine conserved nonameric CD8+ T-cell epitopes specific to the HLA-A*02:01 allele, linked by the spacer sequence EEKK to enhance solubility and prevent epitope interaction. In ex-vivo assays using peripheral blood mononuclear cells (PBMCs) from chronic Chagas disease patients, the recombinant protein successfully recalled antigen-specific immune responses, eliciting the production of interferon-gamma (IFN-γ). It is currently in preclinical development as a human vaccine candidate.
- Other names
- ME proteinT. cruzi multi-epitope proteinTrypanosoma cruzi multi-epitope recombinant protein
02
Targets
HLA-A (HLA class I histocompatibility antigen A alpha chain)
Beyond the preview
Go deeper on T. cruzi multi-epitope recombinant protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T. cruzi multi-epitope recombinant protein.